GENSIGHT BIOLOGICS: GenSight can mitigate Adverum risks into PIONEER data | BUY | EUR18(+99%)
GENSIGHT BIOLOGICS - BUY | EUR18(+99%)GenSight can mitigate Adverum risks into PIONEER data
KOLs surrounding GenSight believe vector is unlikely cause
GenSight has many mitigants at disposal should new risks arise
Early PIONEER data in 2 weeks puts GS030 top of investors mind into REFLECT
Re-iterate BUY and EUR 18 TP into heavy news flow next few months
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.